Cobalt ferrite / graphene nano composite material for drug carrier and preparation method of cobalt ferrite / graphene nano composite material
By modifying polyethylene glycol diamine to combine cobalt ferrite nanoparticles on graphene oxide, the problems of low loading and poor targeting of graphene carriers are solved, and efficient drug loading and acid targeting release are achieved, improving the The effect of anti-cancer treatment.
Patent Information
- Application Number
- CN202411389993.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-08
- Publication Date
- 2024-12-24
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The graphene carrier has low loading and poor targeting, making it difficult to effectively target the delivery of anti-cancer drugs to the tumor site.
The graphene oxide sheet layer was modified by using polyethylene glycol diamine to stabilize the bonding of cobalt ferrite nanoparticles, increase the drug loading and impart the magnetic response and acidic targeting of the carrier.
It significantly improves the load capacity and targeting of drugs, enhances the load capacity of nanomaterials to drugs, and releases drugs more easily in an acidic environment, improving the targeting of tumors.
Smart Images
Figure CN119174824A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of drug carriers, and specifically refers to a cobalt ferrite / graphene nanocomposite material used as a drug carrier and a preparation method thereof. Background Art
[0002] With the development of nanomaterials and the diversification of their functions, their application in cancer treatment has become increasingly widespread. Nanomaterials can not only be used as an independent therapeutic drug, but also as a delivery carrier for a variety of anti-cancer drugs, targeting the delivery of drugs to the tumor site, increasing the enrichment concentration of drugs in the tumor site, achieving multiple functions such as targeted delivery, enriched drug delivery, and synergistic anti-cancer, and are expected to provide a new idea for clinical cancer treatment; graphene oxide is a graphene derivative with a large number of oxygen-containing groups such as carbonyl, hydroxyl, carboxyl and epoxy groups obtained by oxidation of graphene with strong oxidants, ultrasonic crushing or mechanical exfoliation. Graphene oxide is a two-dimensional carbon nanomaterial with advantages such as good biocompatibility, low toxicity and a large specific surface area. It is often used as a nanodrug carrier for targeted delivery of anti-cancer drugs; cobalt ferrite is a magnetic material and a permanent magnetic material. It exhibits strong magnetism at room temperature and can attract magnetic materials such as iron. It is widely used in electronic technology, electromagnetic materials, catalysts and other fields.
[0003] The existing technologies currently have the following main problems: low graphene carrier loading and poor targeting. Summary of the invention
[0004] In view of the above situation, in order to overcome the defects of the prior art, the present invention provides a cobalt ferrite / graphene nanocomposite material for drug carrier and a preparation method thereof. In order to solve the problems of low loading capacity and poor targeting of graphene carrier, the present invention proposes to modify the graphene oxide sheet by using polyethylene glycol diamine, thereby achieving the technical effect of increasing the drug loading capacity. At the same time, the use of cobalt ferrite nanoparticles gives the carrier magnetic response and acidic targeting.
[0005] In order to achieve the above-mentioned purpose, the technical solution adopted by the present invention is as follows: the present invention proposes a cobalt ferrite / graphene nanocomposite material for a drug carrier, wherein the cobalt ferrite / graphene nanocomposite material for a drug carrier comprises the following components in parts by weight: 50-60 parts of graphene oxide, 8-12 parts of polyethylene glycol diamine, and 25-30 parts of cobalt ferrite nanoparticles.
[0006] Preferably, the cobalt ferrite nanoparticles include the following components in parts by weight: 20-30 parts of ferric chloride hexahydrate, 10-15 parts of cobalt chloride hexahydrate, 40-60 parts of polyvinyl pyrrolidone, and 120-140 parts of carbonamide.
[0007] Preferably, the method for preparing the cobalt ferrite nanoparticles specifically comprises the following steps:
[0008] (1) adding ferric chloride hexahydrate to ethylene glycol, and then adding cobalt chloride hydrate, stirring and dissolving to obtain an iron / cobalt solution;
[0009] (2) adding polyvinyl pyrrolidone to the iron / cobalt solution obtained in step (1), stirring in a water bath, then adding carbonamide, maintaining the temperature and stirring for 30 minutes to obtain a mixed solution;
[0010] (3) Add the mixed solution obtained in step (2) into a reaction kettle, react in a forced air drying oven, cool to room temperature, remove non-magnetic and weakly magnetic components by magnetic separation technology, and wash to obtain cobalt ferrite nanoparticles.
[0011] Preferably, in step (1), the amount of ferric chloride hexahydrate added to ethylene glycol is 0.05-0.06 g / mL.
[0012] Preferably, in step (2), the water bath is stirred at a temperature of 60-70° C., a speed of 120-160 rpm, and a time of 90-100 min.
[0013] Preferably, in step (3), the reaction is carried out in the air drying oven at a temperature of 190-210° C. for a time of 12-16 h.
[0014] The present invention also provides a method for preparing a cobalt ferrite / graphene nanocomposite material for a drug carrier, which specifically comprises the following steps:
[0015] S1. Adding graphene oxide to N,N-dimethylformamide, stirring at high speed, and ultrasonically dispersing to obtain a graphene oxide dispersion;
[0016] S2, adding 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride to the graphene oxide dispersion obtained in S1, and adding an equal amount of N-hydroxysuccinimide, stirring at 100 rpm in an ice bath for 100 min to obtain a mixed solution;
[0017] S3, adding polyethylene glycol diamine dropwise into the mixed solution obtained in S2, stirring in a water bath, adding cobalt ferrite nanoparticles, heating and stirring, cooling to room temperature, centrifuging, collecting the precipitate, washing, and drying to obtain a cobalt ferrite / graphene nanocomposite material for a drug carrier.
[0018] Preferably, in S1, the amount of graphene oxide added to N,N-dimethylformamide is 0.6-1.2 mg / mL.
[0019] Preferably, in S2, the amount of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride added to the graphene oxide dispersion obtained in S1 is 18-25 mg / mL.
[0020] Preferably, in S3, the water bath is stirred at a temperature of 40-50°C, a speed of 80-100 rpm, and a time of 120-160 min.
[0021] Preferably, in S3, the heating and stirring is performed at a temperature of 50-60°C, a speed of 120-160 rpm, and a time of 120-160 min.
[0022] The beneficial effects achieved by the invention are as follows: cobalt ferrite nanoparticles are synthesized by using ferric chloride hexahydrate and cobalt chloride hydrate, and impurities are removed by a magnetic separation method to retain magnetic substances, graphene oxide is modified by polyethylene glycol diamine, -NH2 of the polyethylene glycol diamine and -COOH of the graphene oxide are condensed to form -NH-CO- connection, so that graphene sheets are connected by polyethylene glycol, the loading amount of cobalt ferrite nanoparticles is increased, the specific surface area and magnetism of the nanomaterial are increased, and the stability of the combination of graphene oxide nanoparticles and cobalt ferrite particles is enhanced, so as to increase the loading amount of the nanomaterial for drugs, the cobalt ferrite loaded by polyethylene glycol and graphene has no adverse effect on cells, the drug is more easily released in an acidic environment, and is beneficial to microenvironments such as tumors, and has certain targeting. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 The results of the drug loading experiments of Examples 1-3 and Comparative Examples 1-2 of the present invention are shown in FIG.
[0024] Figure 2 This is a result diagram of a load test of Example 1 of the present invention;
[0025] Figure 3 The results of the cytotoxicity test of Example 1-3 are shown in FIG.
[0026] Figure 4 This is an electron microscope image of the cobalt ferrite nanoparticles prepared in Example 1;
[0027] Figure 5 This is an electron microscope image of the cobalt ferrite / graphene nanocomposite material prepared in Example 1;
[0028] Figure 6 Flow chart of graphene oxide modification by polyethylene glycol diamine.
[0029] The accompanying drawings are used to provide further understanding of the present invention and constitute a part of the specification. They are used to explain the present invention together with the embodiments of the present invention and do not constitute a limitation of the present invention. DETAILED DESCRIPTION
[0030] The technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments; based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.
[0031] Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein may be applied to the present invention. The preferred implementation methods and materials described herein are for demonstration purposes only and are not intended to limit the content of this application.
[0032] The experimental methods in the following examples are conventional methods unless otherwise specified; the experimental materials used in the following examples are purchased from commercial channels unless otherwise specified.
[0033] Example 1
[0034] A cobalt ferrite / graphene nanocomposite material for a drug carrier comprises the following components in parts by weight: 60 parts of graphene oxide, 12 parts of polyethylene glycol diamine, and 30 parts of cobalt ferrite nanoparticles.
[0035] The cobalt ferrite nanoparticles include the following components in parts by weight: 30 parts of ferric chloride hexahydrate, 15 parts of cobalt chloride hexahydrate, 60 parts of polyvinyl pyrrolidone, and 140 parts of carbonamide;
[0036] The preparation method of cobalt ferrite nanoparticles specifically comprises the following steps:
[0037] (1) adding ferric chloride hexahydrate in an amount of 0.06 g / mL to ethylene glycol, and then adding cobalt chloride hydrate, stirring and dissolving to obtain an iron / cobalt solution;
[0038] (2) adding polyvinyl pyrrolidone to the iron / cobalt solution obtained in step (1), stirring at 160 rpm in a 70°C water bath for 100 min, then adding carbonamide, maintaining the temperature and stirring for 30 min to obtain a mixed solution;
[0039] (3) The mixed solution obtained in step (2) is added to a reaction kettle, reacted in a forced air drying oven at 210° C. for 16 h, cooled to room temperature, and the non-magnetic and weakly magnetic components are removed by magnetic separation technology, and washed to obtain cobalt ferrite nanoparticles.
[0040] The present invention also provides a method for preparing a cobalt ferrite / graphene nanocomposite material for a drug carrier, which specifically comprises the following steps:
[0041] S1. Adding graphene oxide in an amount of 1.2 mg / mL to N,N-dimethylformamide, stirring at high speed, and ultrasonically dispersing to obtain a graphene oxide dispersion;
[0042] S2, adding 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride at an amount of 25 mg / mL to the graphene oxide dispersion obtained in S1, and adding an equal amount of N-hydroxysuccinimide, stirring at 100 rpm in an ice bath for 100 min to obtain a mixed solution;
[0043] S3. Add polyethylene glycol diamine dropwise into the mixed solution obtained in S2, stir at 100 rpm in a 50°C water bath for 160 min, add cobalt ferrite nanoparticles, heat at 60°C and stir at 160 rpm for 160 min, cool to room temperature, centrifuge, collect the precipitate, wash, and dry to obtain a cobalt ferrite / graphene nanocomposite material for a drug carrier.
[0044] Example 2
[0045] A cobalt ferrite / graphene nanocomposite material for a drug carrier comprises the following components in parts by weight: 50 parts of graphene oxide, 8 parts of polyethylene glycol diamine, and 25 parts of cobalt ferrite nanoparticles.
[0046] The cobalt ferrite nanoparticles include the following components in parts by weight: 20 parts of ferric chloride hexahydrate, 10 parts of cobalt chloride hexahydrate, 40 parts of polyvinyl pyrrolidone, and 120 parts of carbonamide;
[0047] The preparation method of cobalt ferrite nanoparticles specifically comprises the following steps:
[0048] (1) adding ferric chloride hexahydrate in an amount of 0.05 g / mL to ethylene glycol, and then adding cobalt chloride hydrate, stirring and dissolving to obtain an iron / cobalt solution;
[0049] (2) adding polyvinyl pyrrolidone to the iron / cobalt solution obtained in step (1), stirring at 120 rpm in a 60°C water bath for 90 min, then adding carbonamide, maintaining the temperature and stirring for 30 min to obtain a mixed solution;
[0050] (3) The mixed solution obtained in step (2) is added to a reactor, reacted in a 190° C. forced air drying oven for 12 h, cooled to room temperature, and the non-magnetic and weakly magnetic components are removed by magnetic separation technology, and washed to obtain cobalt ferrite nanoparticles.
[0051] The present invention also provides a method for preparing a cobalt ferrite / graphene nanocomposite material for a drug carrier, which specifically comprises the following steps:
[0052] S1. Adding graphene oxide in an amount of 0.6 mg / mL to N,N-dimethylformamide, stirring at high speed, and ultrasonically dispersing to obtain a graphene oxide dispersion;
[0053] S2, adding 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride in an amount of 18 mg / mL to the graphene oxide dispersion obtained in S1, and adding an equal amount of N-hydroxysuccinimide, stirring at 100 rpm in an ice bath for 100 min to obtain a mixed solution;
[0054] S3. Add polyethylene glycol diamine dropwise into the mixed solution obtained in S2, stir at 80 rpm in a 40°C water bath for 120 min, add cobalt ferrite nanoparticles, heat at 50°C and stir at 120 rpm for 130 min, cool to room temperature, centrifuge, collect the precipitate, wash, and dry to obtain a cobalt ferrite / graphene nanocomposite material for a drug carrier.
[0055] Example 3
[0056] A cobalt ferrite / graphene nanocomposite material for a drug carrier comprises the following components in parts by weight: 55 parts of graphene oxide, 10 parts of polyethylene glycol diamine and 27 parts of cobalt ferrite nanoparticles.
[0057] The cobalt ferrite nanoparticles include the following components in parts by weight: 25 parts of ferric chloride hexahydrate, 12 parts of cobalt chloride hexahydrate, 50 parts of polyvinyl pyrrolidone, and 130 parts of carbonamide;
[0058] The preparation method of cobalt ferrite nanoparticles specifically comprises the following steps:
[0059] (1) adding ferric chloride hexahydrate in an amount of 0.055 g / mL to ethylene glycol, and then adding cobalt chloride hydrate, stirring and dissolving to obtain an iron / cobalt solution;
[0060] (2) adding polyvinyl pyrrolidone to the iron / cobalt solution obtained in step (1), stirring at 140 rpm in a 65°C water bath for 95 min, then adding carbonamide, maintaining the temperature and stirring for 30 min to obtain a mixed solution;
[0061] (3) The mixed solution obtained in step (2) is added to a reactor, reacted in a 200° C. forced air drying oven for 14 h, cooled to room temperature, and the non-magnetic and weakly magnetic components are removed by magnetic separation technology, and washed to obtain cobalt ferrite nanoparticles.
[0062] The present invention also provides a method for preparing a cobalt ferrite / graphene nanocomposite material for a drug carrier, which specifically comprises the following steps:
[0063] S1. Adding graphene oxide in an amount of 0.8 mg / mL to N,N-dimethylformamide, stirring at high speed, and ultrasonically dispersing to obtain a graphene oxide dispersion;
[0064] S2, adding 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride at an addition amount of 22 mg / mL to the graphene oxide dispersion obtained in S1, and adding an equal amount of N-hydroxysuccinimide, stirring at 100 rpm in an ice bath for 100 min to obtain a mixed solution;
[0065] S3. Add polyethylene glycol diamine dropwise into the mixed solution obtained in S2, stir at 90 rpm in a 45°C water bath for 140 min, add cobalt ferrite nanoparticles, heat at 55°C and stir at 140 rpm for 140 min, cool to room temperature, centrifuge, collect the precipitate, wash, and dry to obtain a cobalt ferrite / graphene nanocomposite material for a drug carrier.
[0066] Comparative Example 1
[0067] This comparative example provides a cobalt ferrite / graphene nanocomposite material, which differs from Example 1 only in that the components do not contain cobalt ferrite nanoparticles, and the remaining components and component contents are the same as those in Example 1.
[0068] Comparative Example 2
[0069] This comparative example provides a cobalt ferrite / graphene nanocomposite material, which is different from Example 1 only in that the component does not contain polyethylene glycol diamine, and the other components and component contents are the same as those in Example 1.
[0070] Experimental example
[0071] 1. Drug loading experiment
[0072] Taking doxorubicin hydrochloride as the test drug, 5 mg of the cobalt ferrite / graphene nanocomposite material obtained in Example 1-3 and Comparative Example 1-2 was added to 50 mL of 0.02 mg / mL doxorubicin hydrochloride solution, shaken at 50 rpm for 30 min, centrifuged, and the remaining doxorubicin hydrochloride content in the solution was measured as the final amount, and the original content was taken as the initial amount, and the loading rate was calculated by the following formula:
[0073] Loading rate = final amount / initial amount × 100%.
[0074] Figure 1 This is a result diagram of the drug loading experiment of Examples 1-3 and Comparative Examples 1-2 of the present invention. As shown in the figure, the loading rates of Examples 1-3 and Comparative Examples 1-2 are 25.6%, 26.8%, 26.1%, 13.6%, and 18.1%, respectively; the loading rate of Example 1-3 is significantly higher than that of Comparative Example 1-2, indicating that the use of cobalt ferrite and polyethylene glycol diamine increases the drug loading capacity of the cobalt ferrite / graphene nanocomposite material.
[0075] 2. Drug Release Experiment
[0076] The cobalt ferrite / graphene nanocomposite material loaded with doxorubicin hydrochloride obtained in the above-mentioned drug loading experiment example 1 was added to PBS solutions with pH values of 5 and 7, and centrifuged at 5000 rpm for 5 minutes at intervals of 25 minutes. The doxorubicin hydrochloride content in the solution was measured as the release amount. The measurement was performed 4 times in total. The final content in the drug loading experiment was taken as the starting amount. The release rate was calculated using the following formula:
[0077] Release rate = release amount / initial amount × 100%.
[0078] Figure 2 This is a result diagram of the loading experiment of Example 1 of the present invention. As shown in the figure, when the pH is 7, the release rates are 5.6%, 18.6%, 21.1%, and 26.5%, respectively; when the pH is 5, the release rates are 8.6%, 22.5%, 29.1%, and 35.3%, respectively; the release rate at pH 5 is significantly higher than that at pH 7, indicating that the cobalt ferrite / graphene nanocomposite material loaded with doxorubicin hydrochloride is more easily released under acidic conditions, which is conducive to targeted use.
[0079] 3. Cytotoxicity Assay
[0080] Human hepatoma cells (HepG2) were cultured in DMEM medium (10% fetal bovine serum, 100U / mL penicillin-streptomycin solution), the incubator temperature was 37°C, and the CO2 concentration was 5%; logarithmic phase cells were seeded on a 96-well plate, the number of cells per well was 5000, 10uL of culture medium was added to each well, and cultured in an incubator for 24h; the culture medium was removed, and 10ug of the cobalt ferrite / graphene nanocomposite material obtained in Example 1-3 and 90uL of a culture medium containing 1% dimethyl sulfoxide were added to the cells of the experimental group, and 100uL of a culture medium containing 1% dimethyl sulfoxide was added to the cells of the control group, and the culture medium was removed after 12h and dissolved with 1% dimethyl sulfoxide. The blank group was 100uL of a culture medium containing 1% dimethyl sulfoxide, and the absorbance of each group was detected at 570nm using an ELISA reader, and the survival rate was calculated using the following formula:
[0081] Survival rate = (absorbance of experimental group - absorbance of blank group) / (absorbance of control group - absorbance of blank group) × 100%.
[0082] Figure 3 This is a graph showing the results of the cytotoxicity test of Examples 1-3. As shown in the figure, the survival rates of Examples 1-3 are 103%, 106%, and 101%, respectively; the survival rates of Examples 1-3 are all 100% or above, and are non-toxic to cells and have no inhibitory effect on cell division, differentiation, and growth.
[0083] Figure 4This is an electron microscope image of the cobalt ferrite nanoparticles prepared in Example 1. As shown in the figure, the cobalt ferrite nanoparticles prepared are spherical, uniform in size, and complete in morphology.
[0084] Figure 5 This is an electron microscope image of the cobalt ferrite / graphene nanocomposite material prepared in Example 1, as shown in the figure, the cobalt ferrite nanoparticles are uniformly loaded on the graphene sheet.
[0085] Figure 6 This is a flow chart of graphene oxide modification by polyethylene glycol diamine. As shown in the figure, the amino groups on the polyethylene glycol diamine are condensed with the carboxyl groups on the graphene oxide respectively to organically connect the graphene oxide sheets.
[0086] While the embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that many changes, modifications, substitutions and variations can be made to the embodiments without departing from the principles and spirit of the invention.
[0087] The present invention and its implementation methods are described above, which is not restrictive. The drawings are only one of the implementation methods of the present invention, and the actual application is not limited thereto. In short, if ordinary technicians in the field are inspired by it and design methods and embodiments similar to the technical solution without creativity without departing from the purpose of the invention, they should all fall within the protection scope of the present invention.
Claims
1. A cobalt ferrite / graphene nanocomposite material for drug carrier, characterized in that: The invention comprises the following components in parts by weight: 50-60 parts of graphene oxide, 8-12 parts of polyethylene glycol diamine and 25-30 parts of cobalt ferrite nanoparticles; the cobalt ferrite nanoparticles comprise the following components in parts by weight: 20-30 parts of ferric chloride hexahydrate, 10-15 parts of cobalt chloride hexahydrate, 40-60 parts of polyvinyl pyrrolidone and 120-140 parts of carbonamide.
2. A method for preparing the cobalt ferrite / graphene nanocomposite material for drug carrier according to claim 1, characterized in that: The specific steps include: S1. Adding graphene oxide to N,N-dimethylformamide, stirring at high speed, and ultrasonically dispersing to obtain a graphene oxide dispersion; S2, adding 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride to the graphene oxide dispersion obtained in S1, and adding an equal amount of N-hydroxysuccinimide, stirring at 100 rpm in an ice bath for 100 min to obtain a mixed solution; S3, adding polyethylene glycol diamine dropwise into the mixed solution obtained in S2, stirring in a water bath, adding cobalt ferrite nanoparticles, heating and stirring, cooling to room temperature, centrifuging, collecting the precipitate, washing, and drying to obtain a cobalt ferrite / graphene nanocomposite material for a drug carrier.
3. The method for preparing the cobalt ferrite / graphene nanocomposite material for drug carrier according to claim 2, characterized in that: In S1, the amount of graphene oxide added to N,N-dimethylformamide is 0.6-1.2 mg / mL.
4. The method for preparing the cobalt ferrite / graphene nanocomposite material for drug carrier according to claim 3, characterized in that: In S2, the amount of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride added to the graphene oxide dispersion obtained in S1 is 18-25 mg / mL.
5. The method for preparing the cobalt ferrite / graphene nanocomposite material for drug carrier according to claim 4, characterized in that: In S3, the water bath is stirred at a temperature of 40-50°C, a speed of 80-100 rpm, and a time of 120-160 min.
6. The method for preparing the cobalt ferrite / graphene nanocomposite material for drug carrier according to claim 5, characterized in that: In S3, the heating and stirring are performed at a temperature of 50-60°C, a speed of 120-160 rpm, and a time of 120-160 min.
7. The method for preparing the cobalt ferrite / graphene nanocomposite material for drug carrier according to claim 6, characterized in that: The method for preparing the cobalt ferrite nanoparticles specifically comprises the following steps: (1) adding ferric chloride hexahydrate to ethylene glycol, and then adding cobalt chloride hydrate, stirring and dissolving to obtain an iron / cobalt solution; (2) adding polyvinyl pyrrolidone to the iron / cobalt solution obtained in step (1), stirring in a water bath, then adding carbonamide, maintaining the temperature and stirring for 30 minutes to obtain a mixed solution; (3) Add the mixed solution obtained in step (2) into a reaction kettle, react in a forced air drying oven, cool to room temperature, remove non-magnetic and weakly magnetic components by magnetic separation technology, and wash to obtain cobalt ferrite nanoparticles.
8. The method for preparing the cobalt ferrite / graphene nanocomposite material for drug carrier according to claim 7, characterized in that: In step (1), the amount of ferric chloride hexahydrate added to ethylene glycol is 0.05-0.06 g / mL.
9. The method for preparing the cobalt ferrite / graphene nanocomposite material for drug carrier according to claim 8, characterized in that: In step (2), the water bath is stirred at a temperature of 60-70°C, a speed of 120-160 rpm, and a time of 90-100 min.
10. The method for preparing the cobalt ferrite / graphene nanocomposite material for drug carrier according to claim 9, characterized in that: In step (3), the reaction is carried out in the air drying oven at a temperature of 190-210° C. for a time of 12-16 hours.